Fig. 3.1 Imaging studies of the first case that exhibit a symptomatic centrally located cystic lesion with enhancing intramural projections. The cystic lesion abuts the left hepatic duct, producing significant left…
Fig. 8.1 Cross-sectional imaging demonstrating solitary hepatic metastatic disease. a and b Preoperative PET-CT showing segment IVb/V mass. c Restaging following four cycles of neoadjuvant 5-fluorouracil, leucovorin, oxaliplatin, and bevacizumab, showing…
Fig. 6.1 Case 3. a Contrast enhanced T1 weighted MRI of the liver showing multiple liver metastases and segment 4 lesion threatening left portal vein margin. b FDG-18 Positive emission topography…
Ultrasound CT MRI Angiography – Hepatomegaly (early) – Irregular contour – Right lobe and medial left lobe atrophy; lateral left lobe and caudate lobe enlargement – Coarsened echotexture – Arteriovenous…
Primary liver tumors Hepatocellular carcinoma Cholangiocarcinoma Hilar cholangiocarcinoma Gallbladder cancer Metastatic liver disease Colorectal cancer Neuroendocrine tumors Non-colorectal non-neuroendocrine tumors The oncologic appropriateness of surgical resection varies according to the…
Fig. 1.1 Schematic picture of the segments of the liver. The liver can be divided into eight segments based on first and second order divisions of the hepatic artery, portal vein,…
Fig. 15.1 Cholangiocarcinoma classification: a Intrahepatic cholangiocarcinoma: tumors in the bile ducts within the hepatic parenchyma b Extrahepatic cholangiocarcinoma: tumors from the junction of the left and right hepatic ducts to…
Fig. 13.1 Geographic variation in liver cancer incidence (age-standardized). [Reproduced with permission from Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D,…
Author, year of publication Study design # of IHC pts Tumor size (cm3) Mode of RT delivery Total dose (Gy) # Fx One-year LC One-year OS Toxicity Liu et al….
Author; year Design Pts with liver metastases Frx × dose m-FU mts Local control 2-years (%) Survival 1-, 2-years (%) Severe morbidity Schefter 2005 [19] Phase I 18 3 × 12–20 Gy NR NR NR…
